These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 19833826)

  • 21. Genomic-wide cDNA microarray screening to correlate gene expression profile with chemoresistance in patients with advanced lung cancer.
    Oshita F; Ikehara M; Sekiyama A; Hamanaka N; Saito H; Yamada K; Noda K; Kameda Y; Miyagi Y
    J Exp Ther Oncol; 2004 Jul; 4(2):155-60. PubMed ID: 15500010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vascular endothelial growth factor receptor 2 gene polymorphisms as predictors for tumor recurrence and overall survival in non-small-cell lung cancer.
    Uzunoglu FG; Kaufmann C; Wikman H; Güngör C; Bohn BA; Nentwich MF; Reeh M; Pantel K; Bockhorn M; Kutup A; Mann O; Izbicki JR; Vashist YK
    Ann Surg Oncol; 2012 Jul; 19(7):2159-68. PubMed ID: 22395975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A gene signature combining the tissue expression of three angiogenic factors is a prognostic marker in early-stage non-small cell lung cancer.
    Sanmartín E; Sirera R; Usó M; Blasco A; Gallach S; Figueroa S; Martínez N; Hernando C; Honguero A; Martorell M; Guijarro R; Rosell R; Jantus-Lewintre E; Camps C
    Ann Surg Oncol; 2014 Feb; 21(2):612-20. PubMed ID: 24145997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prognostic test for adenocarcinoma of the lung from gene expression profiling data.
    Gordon GJ; Richards WG; Sugarbaker DJ; Jaklitsch MT; Bueno R
    Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):905-10. PubMed ID: 14504202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
    Li B; Cui Y; Diehn M; Li R
    JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blood-based gene expression signatures in non-small cell lung cancer.
    Zander T; Hofmann A; Staratschek-Jox A; Classen S; Debey-Pascher S; Maisel D; Ansén S; Hahn M; Beyer M; Thomas RK; Gathof B; Mauch C; Delank KS; Engel-Riedel W; Wichmann HE; Stoelben E; Schultze JL; Wolf J
    Clin Cancer Res; 2011 May; 17(10):3360-7. PubMed ID: 21558400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chondrolectin is a novel diagnostic biomarker and a therapeutic target for lung cancer.
    Masuda K; Takano A; Oshita H; Akiyama H; Tsuchiya E; Kohno N; Nakamura Y; Daigo Y
    Clin Cancer Res; 2011 Dec; 17(24):7712-22. PubMed ID: 22016508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression level of valosin-containing protein (p97) is correlated with progression and prognosis of non-small-cell lung carcinoma.
    Yamamoto S; Tomita Y; Hoshida Y; Iizuka N; Monden M; Yamamoto S; Iuchi K; Aozasa K
    Ann Surg Oncol; 2004 Jul; 11(7):697-704. PubMed ID: 15231524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients.
    Der SD; Sykes J; Pintilie M; Zhu CQ; Strumpf D; Liu N; Jurisica I; Shepherd FA; Tsao MS
    J Thorac Oncol; 2014 Jan; 9(1):59-64. PubMed ID: 24305008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small-cell lung cancer.
    Zhu ZH; Sun BY; Ma Y; Shao JY; Long H; Zhang X; Fu JH; Zhang LJ; Su XD; Wu QL; Ling P; Chen M; Xie ZM; Hu Y; Rong TH
    J Clin Oncol; 2009 Mar; 27(7):1091-9. PubMed ID: 19188679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High transforming growth factor β expression represents an important prognostic parameter for surgically resected non-small cell lung cancer.
    Sterlacci W; Wolf D; Savic S; Hilbe W; Schmid T; Jamnig H; Fiegl M; Tzankov A
    Hum Pathol; 2012 Mar; 43(3):339-49. PubMed ID: 21840566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival.
    Brabender J; Usadel H; Danenberg KD; Metzger R; Schneider PM; Lord RV; Wickramasinghe K; Lum CE; Park J; Salonga D; Singer J; Sidransky D; Hölscher AH; Meltzer SJ; Danenberg PV
    Oncogene; 2001 Jun; 20(27):3528-32. PubMed ID: 11429699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
    Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection.
    Patnaik SK; Kannisto E; Knudsen S; Yendamuri S
    Cancer Res; 2010 Jan; 70(1):36-45. PubMed ID: 20028859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non-small cell lung cancer.
    Yoon KA; Yoon H; Park S; Jang HJ; Zo JI; Lee HS; Lee JS
    J Thorac Cardiovasc Surg; 2012 Oct; 144(4):794-807. PubMed ID: 22818121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers.
    Nishio M; Koshikawa T; Yatabe Y; Kuroishi T; Suyama M; Nagatake M; Sugiura T; Ariyoshi Y; Mitsudomi T; Takahashi T
    Clin Cancer Res; 1997 Jul; 3(7):1051-8. PubMed ID: 9815783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Analysis of prognostic factors in 1826 patients with completely resected non-small cell lung cancer].
    Gao YS; Xing XZ; Shao K; Feng XL; He J
    Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):134-7. PubMed ID: 18646698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes and efficacy of thoracic surgery biopsy for tumor molecular profiling in patients with advanced lung cancer.
    Cooke DT; Gandara DR; Goodwin NC; Calhoun RF; Lara PN; Mack PC; David EA
    J Thorac Cardiovasc Surg; 2014 Jul; 148(1):36-40. PubMed ID: 24746995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ornithine decarboxylase mRNA expression in curatively resected non-small-cell lung cancer.
    Grimminger PP; Schneider PM; Metzger R; Vallböhmer D; Danenberg KD; Danenberg PV; Hölscher AH; Brabender J
    Clin Lung Cancer; 2010 Mar; 11(2):114-9. PubMed ID: 20199977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
    Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
    Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.